NVAX earnings date and last-quarter result: last quarter beat, P/E -14.65. Updated 2026-07-23.
Novavax (NVAX) Research Hub
Novavax (NVAX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 9.4 USD (-3.09%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -14.65, market cap 1.31B. This hub links to the full technical, earnings and options research available for NVAX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 9.4 USD (-3.09%) |
| 52-week range | 7.15 USD – 13.39 USD |
| Trend regime | Range |
| 14-day RSI | 36.8 (Bearish) |
| Trailing P/E | -14.65 |
| Market cap | 1.31B |
| Dividend yield | 0.00% |
Available research for NVAX
Covered Call on NVAX: how it works, illustrative setup around the real 9.4 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NVAX: how it works, illustrative setup around the real 9.4 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NVAX: how it works, illustrative setup around the real 9.4 USD price, max profit/loss, breakeven and when to use it. Educational.
NVAX technical analysis: range, last 9.4 USD, RSI 36.8, 52w range 7.15 USD–13.39 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is NVAX in?
Novavax (NVAX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NVAX in an uptrend or downtrend?
As of 2026-10-26, NVAX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NVAX's trailing P/E ratio?
NVAX's trailing P/E is -14.65, with a market cap of 1.31B. See the earnings research page for full valuation detail.